Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells

Korean Journal of Physiology and Pharmacology

Volumn 12, Issue 4, 2008, Pages 165-170

  Park, So Youn ^a   Lee, Jeong Hyun ^a   Shin, Hwa Kyoung ^a   Kim, Chi Dae ^a   Lee, Won Suk ^a   Rhim, Byung Yong ^a   Shin, Yung Woo ^a   Hong, Ki Whan ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Cilostazol; Endothelial cells; MCP 1; Monocyte adhesion; Probucol; Synergism; VCAM 1

Indexed keywords

CILOSTAZOL; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROBUCOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MONOTHERAPY; OXIDATIVE STRESS; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

EID: 52249121365     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: 10.4196/kjpp.2008.12.4.165     Document Type: Article

References (30)

1. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 45: 361-378, 1994
2. Bilenko MV, Khirchenko AV, Konovalova GG, Lankin VZ. Effect of antioxidant probucol on cell-mediated LDL oxidation in vitro and in vivo. Bull Exp Biol Med 136: 126-128, 2003
3. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84: 7725-7772, 1987
4. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300: 787-793, 2002
5. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos J-C, Connelly PW, Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107: 1255-1262, 2001
6. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 21: 662-667, 2001
7. Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 94: 92-600, 1994
8. Ferns GA, Forster L, Stewart-Lee A, Nourooz-Zadeh J, Anggard EE. Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis 100: 171-181, 1993
9. Fruebis J, Gonzalez V, Silvestre M, Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 17: 1289-1302, 1997
10. Fruebis J, Silvestre M, Shelton D, Napoli C, Palinski W. Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits. J Lipid Res 40: 1958-1966, 1999
11. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281, 1998
12. Hang KW, Kim KY, Shin HK, Lee JH, Choi JM, Kwak YG, Kim CD, Lee WS, Rhim BY. Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 306: 1182-1190, 2003
13. Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgoard J, Holme I, Walldius G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol 15: 1049-1056, 1995
14. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharide-induced apoptosis by cilostazal in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300: 709-715, 2002
15. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35: 1144-1149, 1985
16. Kockx MM. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 18: 1519-1522, 1998
17. Kuzuya M, Kuzuya F. Probucel as an antioxidant and antiatherogenic drug. Free Radic Biol Med 14: 67-77, 1993
18. Li PF, Dietz R, von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 96: 3602-3609, 1997
19. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91: 2844-2850, 1995
20. Mallikaarjun S, Forbes WP, Bramer SL. Interaction potential and tolerability of the coadministration of cilostazol and aspirin. Clin Pharmacokinet 37 Suppl 2: 87-93, 1999
21. Park SY, Lee JH, Kim CD, Lee WS, Park WS, Han J, Kwak Y-G, Kim KY, Hong KW. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther 317: 1238-1245, 2006
22. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, Hong KW. Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res 1157: 112-120, 2007
23. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, Hong KW. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 312: 1241-1248, 2005
24. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 147: 213-225, 1999
25. Reinoehl J, Frankovich D, Machado C, Kawasaki R, Baga JJ, Pires LA, Steinman RT, Fromm BS, Lehmann MH. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 131: 1184-1191, 1996
26. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993
27. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82: 144-147, 1998
28. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109: 1022-1028, 2004
29. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 337: 365-372, 1997
30. Zapolska-Downar D, Zapolski-Downar A, Markiewski M, Ciechanowicz A, Kaczmarczyk M, Naruszewicz M. Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells. Atherosclerosis 155: 123-130, 2001